ANNOUNCEMENT

NOBEL PRIZE 2026

This year's laureates, their fields, and the discoveries that earned them the prize.Live nowSee the winners
Moonbase
← Back to Awards
NIHNATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESR01

Cellular Determinants and Function Consequences of PP2A-B56 Degradation by HIV-1 Vif

Active
Institution
Icahn School of Medicine at Mount Sinai, NY
Principal investigator
Jeffrey R Johnson
Funding
$551K
Duration
2023–2027
Open portfolio

Moonbase score

Still being scored

Abstract

PROJECT SUMMARY The HIV-1 Vif protein is expressed late during infection and has a well-described function to ubiquitinate and degrade proteins in the APOBEC3 family, thus neutralizing their antiviral activities. More recently, an additional function of HIV-1 Vif was described by us and others to ubiquitinate and degrade protein phosphatase 2A holoenzymes containing B56 family regulatory subunits (PP2A-B56). The conservation of Vif-mediated PP2A- B56 degradation throughout globally circulating HIV-1 subtypes suggests that it is functionally important. However, there remains a gap in understanding the mechanisms by which PP2A-B56 degradation confers a fitness advantage to HIV-1. Furthermore, in contrast to APOBEC3 degradation, the host cellular determinants required for Vif-mediated ubiquitination and degradation of PP2A-B56 are undefined. In this project, we aim to address these gaps in understanding by defining the cellular determinants and functional effects of PP2A-B56 degradation by HIV-1 Vif. In Aim 1, we will apply unbiased protein interaction technologies to determine proteins interacting with PP2A-B56 while it is degraded by Vif. In Aim 2, we will carry out a genome- wide CRISPR/Cas9 genetic screen to identify genes regulating APOBEC3 and PP2A-B56 degradation. In Aim 3, will test the impact of individual phosphorylation sites regulated by PP2A-B56 in HIV-1 replication in primary CD4+ T cells. Successful completion of this project will advance understanding of the Vif-PP2A-B56 signaling axis, potentially leading towards the development of novel classes of antiretroviral therapies that target late processes of HIV-1 infection.

LOADING MOONBASE SCORE

R01NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESHIV Molecular Virology, Cell Biology, and Drug Development Study Section[HVCD]determinantsdegradationdegradegenetic screenprotein interactionscreen identifylatehiv-

Questions for Icahn School of Medicine at Mount Sinai

Answered by the team behind this research.

Same researchers, same institution, same topic, scored first.